spironolactone has been researched along with Muscle Weakness in 7 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary hyperaldosteronism is characterised by hypertension, hypokalemia, suppressed plasma renin activity, and increased aldosterone excretion." | 2.45 | Rhabdomyolysis due to primary hyperaldosteronism. ( Corrales, PP; López, AH; Martínez, JJ; Meneses, AL; Oliveira, CL; Rodríguez, SA; Romero, FB, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Martínez, JJ | 1 |
| Oliveira, CL | 1 |
| Meneses, AL | 1 |
| Rodríguez, SA | 1 |
| Corrales, PP | 1 |
| López, AH | 1 |
| Romero, FB | 1 |
| LAPRESLE, J | 1 |
| BOUDIN, G | 1 |
| GOULON, M | 1 |
| HAMBURGER, J | 1 |
| LHERMITTE, F | 1 |
| PEQUIGNOT, H | 1 |
| LEFEVRE, JP | 1 |
| FERRARI, G | 1 |
| VIO, M | 1 |
| JEUNE, M | 1 |
| VINCENT, P | 1 |
| HUMBERT, G | 1 |
| LEVRAT, R | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
1 review available for spironolactone and Muscle Weakness
| Article | Year |
|---|---|
Rhabdomyolysis due to primary hyperaldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Female; Humans; Hyperaldosteronism; Hyperten | 2009 |
6 other studies available for spironolactone and Muscle Weakness
| Article | Year |
|---|---|
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
[HOW TO TREAT MYASTHENIA].
Topics: Ambenonium Chloride; Ephedrine; Humans; Muscle Weakness; Myasthenia Gravis; Neostigmine; Physostigmi | 1964 |
[PRACTICAL TREATMENT OF MYASTHENIA].
Topics: Adrenal Cortex Hormones; Cholinesterase Inhibitors; Drug Therapy; Humans; Muscle Weakness; Myastheni | 1964 |
[5 CASES OF MYASTHENIA TREATED WITH SPIRONOLACTONE (SC9420 LEPETIT)].
Topics: Humans; Muscle Weakness; Myasthenia Gravis; Spironolactone | 1964 |
[Preliminary note on the use of a spirolactone in the treatment of myasthenia].
Topics: Aldosterone; Humans; Mineralocorticoid Receptor Antagonists; Muscle Weakness; Myasthenia Gravis; Spi | 1962 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperka | 2004 |